The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...

According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.

The medicine hit its primary endpoint of a decrease in the average daily leg pain intensity as measured by the Numeric Pain ...

M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease ...

Vertex is best known for its therapies for the rare lung disease cystic fibrosis (CF). Its steady work over the year delivered a large market share in CF therapies. Coming off of Novo Nordisk's ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...

The top 10 pharmaceutical stocks are released! Hengrui Medicine aims to hit a market value of 370 billion yuan ASH | BTK inhibitor development trends: Eli Lilly, BeiGene, and AZ announce clinical resu ...

Access to these treatments is provided under the terms of an interim commercial agreement reached between Vertex and NHS England, with the full support of NICE. “NHS England remains committed to ...